Day: January 29, 2024

Marimekko Corporation, Stock Exchange Release, 29 January 2024 at 10.30 a.m. Shareholders’ proposals to the Annual General Meeting for the number of Marimekko’s Board members, the composition of the Board and its remuneration Shareholders representing in total approximately 27 percent of all the shares and votes of Marimekko Corporation have made a proposal to the Annual General Meeting to be held on 16 April 2024 for the number of members of the Board of Directors, the composition of the Board and its remuneration. Proposal for the number of members of the Board of Directors Shareholders who represent approximately 27 percent of all the shares and votes of Marimekko Corporation have informed the company that they propose to the Annual General Meeting that six (6) members be elected to the Board of Directors. Proposal for the composition...

 The study, which assessed the pharmacokinetics, safety, and tolerability of AVT03 compared to Prolia® in healthy adult subjects, met its primary endpoints Prolia® and Xgeva® (denosumab) are indicated for the treatment of bone diseaseAlvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, announced today positive top-line results from a pharmacokinetic (PK) study for AVT03, a biosimilar candidate to Prolia® and Xgeva®, which both contain denosumab. The PK study (AVT03-GL-P01), which assessed the pharmacokinetics, safety, and tolerability of AVT03 compared to Prolia® in healthy adult subjects, met its primary endpoints. A confirmatory efficacy study for AVT03 in patients is currently underway, as well as a PK study comparing AVT03 to Xgeva® in...

ORION CORPORATION PRESS RELEASE 29 JANUARY 2024 at 11.00 EET          Orion Corporation and Newel Health enter into licensing agreement for a digital therapeutic (DTx) ODD-403 (“Rohkea”) in pain Orion Corporation (“Orion”) and Newel Health (“Newel”) have entered into a license agreement regarding ODD-403 (“Rohkea”), a digital therapeutic (DTx) developed by Orion for patients suffering from chronic pain and particularly from fear of movement and re-injury. Under the terms of the agreement, Newel will have the exclusive global rights to develop, manufacture and commercialise ODD-403. Orion is entitled to receive royalty from the sales of the product as well as sales milestone payments. “Newel is one of the frontrunners in digital therapeutic (DTx) applications, and we are pleased to have them as our partner in this indication area. We believe...

The study, which assessed the pharmacokinetics, safety, and tolerability of AVT03 compared to Prolia® in healthy adult subjects, met its primary endpoints Prolia® and Xgeva® (denosumab) are indicated for the treatment of bone diseaseREYKJAVIK, Iceland, Jan. 29, 2024 (GLOBE NEWSWIRE) — Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, announced today positive top-line results from a pharmacokinetic (PK) study for AVT03, a biosimilar candidate to Prolia® and Xgeva®, which both contain denosumab. The PK study (AVT03-GL-P01), which assessed the pharmacokinetics, safety, and tolerability of AVT03 compared to Prolia® in healthy adult subjects, met its primary endpoints. A confirmatory efficacy study for AVT03 in patients is currently underway,...

The Stockwik Board of Directors today decided to appoint Urban Lindskog as the CEO of the company. Urban Lindskog brings with him extensive experience from leading positions and board assignments in Swedish enterprises. Urban Lindskog’s background includes experience as a successful CEO of several technology companies with international operations, such as Scanmast, Dafo Vehicle, Metria, and recently as head of a division in the industry group, Lagercrantz Group. He also has extensive experience as Board member and Chairman, including as Vice chairman of the The Sixth Swedish National Pension Fund, as well as having been Chairman of the Board for the public company Glocalnet. Since 2023, Urban Lindskog serves on the Board of Directors of Green Cargo. “The appointment of Urban Lindskog as the new CEO is an important step for Stockwik....

EDMONTON, Alberta, Jan. 29, 2024 (GLOBE NEWSWIRE) — Regenx Tech Corp., (the “Company” or “Regenx”) (CSE: RGX) (OTCQB: RGXTF) (FSE: YRS WKN:A2DSW3) announces that it has closed the previously announced unsecured and non-brokered Convertible Debenture Financing (“Offering”) for gross proceeds of $1,600,401.73. The Debentures will bear interest at the rate of fifteen percent (15%) per annum, payable on the maturity date and will mature on December 31, 2025. The Debentures will be convertible at the holder’s option into common shares of the Corporation (“Common Shares”) at a conversion price of: (i) $0.05 per Common Share until the date that is one (1) year from the closing date; and (ii) $0.105 per Common Share for the period from the date following one (1) year from the closing date until the maturity date....

Geneva, Switzerland, Jan. 29, 2024 (GLOBE NEWSWIRE) — For more information visit: https://www.youtube.com/watch?v=nxN0UbAvA54 WISeKey International Holding Ltd. (“WISeKey”) (SIX: WIHN, NASDAQ: WKEY), a global leader in cybersecurity, digital identity, and Internet of Things (IoT) solutions operating as a holding company, today celebrates its 25th anniversary by unveiling a strategic reorganization toward Web 3.0, exemplifying a new era of a neutral, secure, and decentralized internet. This transition underscores WISeKey’s enduring commitment to innovation and its pioneering role in the digital landscape since its inception in 1999. Pioneering the Web 3.0 Paradigm: From its early days as a trailblazer in identity management and secure digital processes, WISeKey now spearheads the Web 3.0 revolution. This paradigm shift embraces...